Ketoconazole
FDA-approved product (tablet, oral), marketed as Extina, Ketoconazole, Ketozole and 3 more.
- Registered studies
- 50+
- Lab records
- 1
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Adrenal gland disease
- Blastomycosis
- Cushing syndrome
- Seborrheic dermatitis
- Tinea
- Tinea pedis
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Imidazole and triazole derivatives; Imidazole derivatives; Anticorticosteroids
- FDA pharmacologic class
- Azole Antifungal FDA label ↗
- Anti-infective classification
- Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC D01AC08; WHO ATC G01AF11; WHO ATC J02AB02; FDA class Azole Antifungal
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA63.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli33.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae27.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis81.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
- M. tuberculosis: measured active in 1 of 1 lab record
Show the 1 laboratory record, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Ketoconazole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- DactinomycinExisting use: Kidney Wilms tumor, Neoplasm95.6% AI-predicted activityagainst MRSALab records exist50+ registered studies
- TaurursodiolExisting use: Bile acids and derivatives79.6% AI-predicted activityagainst MRSA43 registered studies
- LinaclotideExisting use: Constipation, Constipation disorder, Irritable bowel syndrome74.5% AI-predicted activityagainst MRSA50+ registered studies
- PlecanatideExisting use: Constipation74.4% AI-predicted activityagainst MRSA15 registered studies
- OxytocinExisting use: Hemorrhage, Uterine Inertia74.2% AI-predicted activityagainst MRSA50+ registered studies
- PosaconazoleExisting use: Aspergillosis, Candidiasis, Coccidioidomycosis and 2 more72.2% AI-predicted activityagainst MRSA50+ registered studies
- SotorasibExisting use: Neoplasm, Non-small cell lung carcinoma70.6% AI-predicted activityagainst MRSA50+ registered studies
- TemsirolimusExisting use: Cancer, Clear cell renal carcinoma, Mantle cell lymphoma and 2 more70.1% AI-predicted activityagainst MRSA50+ registered studies
- Quizartinib DihydrochlorideExisting use: Acute myeloid leukemia, Myeloid leukemia70.0% AI-predicted activityagainst MRSA4 registered studies
- Irinotecan HydrochlorideExisting use: Adenocarcinoma, Cancer, Carcinoma and 4 more70.0% AI-predicted activityagainst MRSA50+ registered studies
- Deoxycholic AcidExisting use: Other dermatologicals69.3% AI-predicted activityagainst MRSA50+ registered studies
- ChenodiolExisting use: Cerebrotendinous xanthomatosis, Inborn errors of metabolism69.2% AI-predicted activityagainst MRSA30 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Comparison of the Efficacy of Topical Luliconazole 2% Cream vs Topical Ketoconazole 1% Cream in the Treatment of Pityriasis Versicolor.
NCT07333170 · start 2026-02
Registered record
- Registry ID
- NCT07333170
- Conditions
- Pityriasis Versicolor
- Interventions
- Luliconazole Cream 1%; Topical ketoconazole 2% cream
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Not yet recruiting
- Start
- 2026-02
- Completion
- 2026-11
- Enrolment
- 86
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPityriasis VersicolorInterventionLuliconazole Cream 1%; Topical ketoconazole 2% creamPhasePhase 4Registry statusNot yet recruitingAzoles Targeting Recurrent High Grade Gliomas
NCT03763396 · start 2024-06-01
Registered record
- Registry ID
- NCT03763396
- Conditions
- Brain Tumor, Recurrent; Cancer, Advanced; Glioma of Brain
- Interventions
- Ketoconazole (KCZ); Posaconazole (PCZ)
- Study type
- INTERVENTIONAL
- Phase
- Early phase 1
- Registry status
- Not yet recruiting
- Start
- 2024-06-01
- Completion
- 2027-06
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBrain Tumor, Recurrent; Cancer, Advanced; Glioma of BrainInterventionKetoconazole (KCZ); Posaconazole (PCZ)PhaseEarly phase 1Registry statusNot yet recruitingKetoconazole Contributes to Cryptorchidism Outcome Via Modulating Macrophage Trem2
NCT06560086 · start 2024-02-03
Registered record
- Registry ID
- NCT06560086
- Conditions
- Cryptorchidism
- Interventions
- Ketoconazole; Luteinizing Hormone
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2024-02-03
- Completion
- 2024-12-31
- Enrolment
- 10
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCryptorchidismInterventionKetoconazole; Luteinizing HormonePhaseNot applicableRegistry statusUnknownAssessment of the Efficacy of Topical Ketoconazole 2% Cream in Comparison With Topical Retinoids in the Treatment of Mild Comedonal and Papulopustular Acne
NCT07237763 · start 2024-01-15
Registered record
- Registry ID
- NCT07237763
- Conditions
- Acne
- Interventions
- advised to apply topical ketoconazole 2% cream twice daily on the whole face.; topical adapalene to the face
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Active not recruiting
- Start
- 2024-01-15
- Completion
- 2025-12
- Enrolment
- 52
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcneInterventionadvised to apply topical ketoconazole 2% cream twice daily on the whole face.; topical adapalene to the facePhaseNot applicableRegistry statusActive not recruiting8% Sulphur-Aloe Vera Soap as an Adjuvant Treatment for Pityriasis Versicolor
NCT06170333 · start 2023-08-25
Registered record
- Registry ID
- NCT06170333
- Conditions
- Pityriasis Versicolor
- Interventions
- 8% sulphur and A. vera soap
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2023-08-25
- Completion
- 2024-01-31
- Enrolment
- 42
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPityriasis VersicolorIntervention8% sulphur and A. vera soapPhasePhase 4Registry statusCompletedAnticoagulation in ICH Survivors for Stroke Prevention and Recovery
NCT03907046 · start 2020-01-28
Registered record
- Registry ID
- NCT03907046
- Conditions
- Intracerebral Hemorrhage; Atrial Fibrillation
- Interventions
- Apixaban; Aspirin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Recruiting
- Start
- 2020-01-28
- Completion
- 2027-04
- Enrolment
- 700
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionIntracerebral Hemorrhage; Atrial FibrillationInterventionApixaban; AspirinPhasePhase 3Registry statusRecruitingITT-5 Mechanisms of Spermatogenesis in Man
NCT02147964 · start 2019-06
Registered record
- Registry ID
- NCT02147964
- Conditions
- Gonadotropin Deficiency
- Interventions
- Testosterone 1% Gel; Acyline; Dutasteride; Ketoconazole; HCG; placebo dutasteride; placebo ketoconazole
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Withdrawn
- Start
- 2019-06
- Completion
- 2026-12
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGonadotropin DeficiencyInterventionTestosterone 1% Gel; Acyline; Dutasteride; Ketoconazole +3 morePhasePhase 2Registry statusWithdrawnObservational Registry on Patients With Endogenous CS to Document Safety and Effectiveness of Ketoconazole.
NCT04872920 · start 2018-12-20
Registered record
- Registry ID
- NCT04872920
- Conditions
- Cushing Syndrome
- Interventions
- Not recorded
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Unknown
- Start
- 2018-12-20
- Completion
- 2024-03-01
- Enrolment
- 200
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCushing SyndromeInterventionNot recordedPhaseNot recordedRegistry statusUnknownKetoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash
NCT03471364 · start 2018-09-25
Registered record
- Registry ID
- NCT03471364
- Conditions
- Malignant Neoplasm
- Interventions
- Ketoconazole; Laboratory Biomarker Analysis; Placebo Administration; Quality-of-Life Assessment; Questionnaire Administration
- Study type
- INTERVENTIONAL
- Phase
- Early phase 1
- Registry status
- Completed
- Start
- 2018-09-25
- Completion
- 2024-09-15
- Enrolment
- 58
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMalignant NeoplasmInterventionKetoconazole; Laboratory Biomarker Analysis; Placebo Administration; Quality-of-Life Assessment +1 morePhaseEarly phase 1Registry statusCompletedThe Comparative Assessment of Mycological Efficacy, Safety, Recurrence, and Cost-effectiveness of Selenium Sulfide 1.8% Shampoo Versus Ketoconazole 2% Shampoo in Pityriasis Versicolor: a Double-blind Randomized Controlled Trial
NCT04007237 · start 2018-09-01
Registered record
- Registry ID
- NCT04007237
- Conditions
- Pityriasis Versicolor
- Interventions
- shampoo with different composition
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2018-09-01
- Completion
- 2018-12-30
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPityriasis VersicolorInterventionshampoo with different compositionPhasePhase 4Registry statusCompletedHormonal Mechanisms of Sleep Restriction - Axis Study
NCT03142893 · start 2017-05-08
Registered record
- Registry ID
- NCT03142893
- Conditions
- Sleep Restriction
- Interventions
- Ketoconazole Pill; Ganirelix; Dexamethasone; Dexamethasone Injection; Cosyntropin Injectable Product; Recombinant Human Luteinizing Hormone; Hydrocortisone Injection; Gonadorelin; Corticorelin; Placebo oral capsule; Saline Solution; Saline Solution for Injection
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Active not recruiting
- Start
- 2017-05-08
- Completion
- 2026-06-30
- Enrolment
- 80
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSleep RestrictionInterventionKetoconazole Pill; Ganirelix; Dexamethasone; Dexamethasone Injection +8 morePhasePhase 1Registry statusActive not recruitingOral Calcitriol With Ketoconazole in CRPC
NCT03261336 · start 2017-01-06
Registered record
- Registry ID
- NCT03261336
- Conditions
- Castration-resistant Prostate Cancer
- Interventions
- Calcitriol, Ketoconazole, Hydrocortisone
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2017-01-06
- Completion
- 2018-02-28
- Enrolment
- 1
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCastration-resistant Prostate CancerInterventionCalcitriol, Ketoconazole, HydrocortisonePhasePhase 2Registry statusTerminatedHormonal Mechanisms of Sleep Restriction
NCT02256865 · start 2014-10
Registered record
- Registry ID
- NCT02256865
- Conditions
- Insulin Resistance
- Interventions
- Ketoconazole; Hydrocortisone; Testosterone; Placebo for ketoconazole; Placebo for hydrocortisone; Placebo for testosterone
- Study type
- INTERVENTIONAL
- Phase
- Early phase 1
- Registry status
- Completed
- Start
- 2014-10
- Completion
- 2023-10
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInsulin ResistanceInterventionKetoconazole; Hydrocortisone; Testosterone; Placebo for ketoconazole +2 morePhaseEarly phase 1Registry statusCompletedTreatment for Endogenous Cushing's Syndrome
NCT01838551 · start 2014-08
Registered record
- Registry ID
- NCT01838551
- Conditions
- Endogenous Cushing's Syndrome
- Interventions
- Levoketoconazole
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2014-08
- Completion
- 2018-11
- Enrolment
- 94
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEndogenous Cushing's SyndromeInterventionLevoketoconazolePhasePhase 3Registry statusCompletedA Study of Baricitinib When Administered With Ketoconazole or Fluconazole in Healthy Participants
NCT01924299 · start 2013-08
Registered record
- Registry ID
- NCT01924299
- Conditions
- Healthy Volunteers
- Interventions
- Baricitinib; Ketoconazole; Fluconazole
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2013-08
- Completion
- 2013-11
- Enrolment
- 36
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy VolunteersInterventionBaricitinib; Ketoconazole; FluconazolePhasePhase 1Registry statusCompleted